A comprehensive review of immunotherapies in prostate cancer

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

A Perspective of Immunotherapy for Prostate Cancer

Recent advances in immuno-oncology and its application to urological cancers

Oncolytic virotherapy for urological cancers

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer

A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment